Last updated: 25 January 2024 at 6:15am EST

Pharmaceutical Co Ltd Takeda Net Worth




The estimated Net Worth of Pharmaceutical Co Ltd Takeda is at least $129 Million dollars as of 24 January 2024. Pharmaceutical Takeda owns over 3,703,703 units of Phathom Pharmaceuticals Inc stock worth over $70,229,402 and over the last 3 years Pharmaceutical sold PHAT stock worth over $58,476,503.

Pharmaceutical Takeda PHAT stock SEC Form 4 insiders trading

Pharmaceutical has made over 22 trades of the Phathom Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Pharmaceutical sold 3,703,703 units of PHAT stock worth $29,999,994 on 24 January 2024.

The largest trade Pharmaceutical's ever made was selling 3,703,703 units of Phathom Pharmaceuticals Inc stock on 24 January 2024 worth over $29,999,994. On average, Pharmaceutical trades about 223,474 units every 45 days since 2021. As of 24 January 2024 Pharmaceutical still owns at least 3,755,583 units of Phathom Pharmaceuticals Inc stock.

You can see the complete history of Pharmaceutical Takeda stock trades at the bottom of the page.



What's Pharmaceutical Takeda's mailing address?

Pharmaceutical's mailing address filed with the SEC is 1-1, NIHONBASHI-HONCHO 2-CHOME, , CHUO-KU, TOKYO, M0, 103-8668.

Insiders trading at Phathom Pharmaceuticals Inc

Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper, and Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.



What does Phathom Pharmaceuticals Inc do?

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.



Complete history of Pharmaceutical Takeda stock trades at Phathom Pharmaceuticals Inc

Insider
Trans.
Transaction
Total value
Pharmaceutical Co Ltd Takeda
10% owner
Sale $29,999,994
24 Jan 2024
Pharmaceutical Co Ltd Takeda
10% owner
Sale $342
14 Mar 2022
Pharmaceutical Co Ltd Takeda
10% owner
Sale $20,850,021
4 Nov 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $91,445
7 Jul 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $292,742
1 Jul 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $869,540
25 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $388,227
23 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $331,702
21 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $305,562
17 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $99,080
14 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $115,881
9 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $82,858
7 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $151,274
2 Jun 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $723,371
28 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $766,677
26 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $773,968
24 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $665,483
20 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $3,500
14 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $420,885
12 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $35,415
7 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $250,829
5 May 2021
Pharmaceutical Co Ltd Takeda
10% owner
Sale $1,257,704
3 May 2021


Phathom Pharmaceuticals Inc executives and stock owners

Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: